Regional infrastructure tied to inappropriate breast, prostate cancer imaging
the ONA take:
Danil Makarov, MD, MHS, of the New York University School of Medicine and fellow researchers user SEER-Medicare data to identify patients with low-risk prostate or breast cancer.
While these two cancers affect different patient populations and therefore should not share an association in imaging, the researchers found a correlation between regional rates, leading them to believe that regional behaviors share common determinants.
They identified 9,2119 men with prostate cancer and 30,398 women with breast cancer in 84 hospital referral regions, with rates of inappropriate imaging found to be 44.4 percent and 41.8 percent, respectively.
Inappropriate prostate cancer imaging rates were associated with those of breast cancer rates at the hospital referral region level. This meant that a man with low-risk prostate cancer had a higher chance of undergoing inappropriate imaging if he lived in a hospital referral region with higher inappropriate breast cancer imaging levels.
“Our findings suggest that practice patterns may be a function of local propensities for health care utilization,” the authors stated. “This is a novel finding with great relevance to cancer policy.”
Regional infrastructure could contribute to inappropriate imaging in patients at risk for prostate and breast cancer.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Definitive IMRT Associated With Shorter Feeding Tube Placement Duration in HNC
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|